Several specific inhibitors have been successfully developed and approved for cancer treatment. Some prominent examples include:
- Imatinib: Targets the BCR-ABL protein in chronic myeloid leukemia (CML). - Trastuzumab: Targets the HER2 receptor in HER2-positive breast cancer. - Erlotinib: Targets the epidermal growth factor receptor (EGFR) in non-small cell lung cancer (NSCLC).
